# US 2024/0197828 A1 · Chimeric molecule to treat sepsis and other inflammatory conditions > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2024/0197828 A1 - Document ID: US20240197828A1 - Status: Published application - Kind: A1 - Application number: 18/538,023 - Filed: 2023-12-13 - Published: 2024-06-20 - Earliest claimed: 2022-12-20 - Assignees: The Feinstein Institutes for Medical Research - Applicants: The Feinstein Institutes for Medical Research - Inventors: Ping Wang; Colleen Nofi; Monowar Aziz; Max Brenner - Web page: https://patentgrep.com/patent/US20240197828A1 ## CPC - A61K 38/1808: {Epidermal growth factor [EGF] urogastrone} - A61K 38/1709: {from mammals} - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Milk fat globule-epidermal growth factor—factor VIII (MFG-E8) derived oligopeptides and pharmaceutical compositions containing the oligopeptides are provided for treating sepsis and inflammatory conditions. ## Claims ### Claim 1 a method of treating a subject with sepsis or with an inflammatory condition comprising administering to the subject a therapeutic amount of a peptide selected from the group consisting of one or more of MOP3, MOP3H, MOP8 and MOP14, or a nucleic acid encoding the peptide, wherein MOP3 has the amino acid sequence (SEQ ID NO. 1) RGDSSSYKTWNLRAFGWY, MOP3H has the amino acid sequence (SEQ ID NO. 16) RGDSSSYKTWGLHLFSWN, MOP8 has the amino acid sequence (SEQ ID NO: 8) RGDVTGIITQGARDFGHI, and MOP14 has the amino acid sequence (SEQ ID NO: 14) RGDPFMARYVRVLPVSWH. ### Claim 2 (depends on 1) the method of claim 1, consisting of administering one or both of MOP3 and MOP3H to the subject. ### Claim 3 (depends on 1) The method of claim 1, wherein treatment of the subject with the peptide reduces tissue injury in the subject compared to tissue injury that would occur in the absence of treatment with the peptide. ### Claim 4 (depends on 3) The method of claim 3, wherein lung injury is reduced by treatment of the subject with the peptide. ### Claim 5 (depends on 1) The method of claim 1, wherein the inflammatory condition is one or more of appendicitis, peptic, gastric or duodenal ulcers, peritonitis, pancreatitis, ulcerative colitis, pseudomembranous, acute or ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, cholecystitis, hepatitis, inflammatory bowel disease, Crohn's disease, enteritis, Whipple's disease, asthma, allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, necrotizing enterocolitis, cachexia, hyperpyrexia, eosinophilic granuloma, granulomatosis, sarcoidosis, septic abortion, epididymitis, vaginitis, prostatitis, urethritis, bronchitis, emphysema, rhinitis, cystic fibrosis, pneumonitis, pneumoultramicroscopicsilicovolcanoconiosis, alveolitis, bronchiolitis, pharyngitis, pleurisy, sinusitis, influenza, respiratory syncytial virus infection, herpes infection, HIV infection, hepatitis B virus infection, hepatitis C virus infection, disseminated bacteremia, Dengue fever, candidiasis, malaria, filariasis, amebiasis, hydatid cysts, bums, dermatitis, dermatomyositis, sunburn, urticaria, warts, wheals, vasculitis, angiitis, endocarditis, arteritis, atherosclerosis, thrombophlebitis, pericarditis, myocarditis, myocardial ischemia, periarteritis nodosa, rheumatic fever, coeliac disease, congestive heart failure, adult respiratory distress syndrome, Alzheimer's disease, meningitis, encephalitis, multiple sclerosis, cerebral infarction, cerebral embolism, Guillain-Barre syndrome, neuritis, neuralgia, spinal cord injury, paralysis, uveitis, arthritides, arthralgias, osteomyelitis, fasciitis, Paget's disease, gout, periodontal disease, rheumatoid arthritis, synovitis, myasthenia gravis, thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, Behcet's syndrome, allograft rejection, graft-versus-host disease, ankylosing spondylitis, Type I diabetes, ankylosing spondylitis, Berger's disease, reactive arthritis (Reiter's syndrome) or Hodgkin's disease. ### Claim 6 (depends on 1) The method of claim 1, wherein the inflammatory condition is one or more of appendicitis, peptic, gastric or duodenal ulcers, peritonitis, pancreatitis, ulcerative colitis, pseudomembranous, acute or ischemic colitis, hepatitis, Crohn's disease, asthma, allergy, anaphylactic shock, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, necrotizing enterocolitis, cachexia, septic abortion, disseminated bacteremia, burns, Alzheimer's disease, coeliac disease, congestive heart failure, adult respiratory distress syndrome, cerebral infarction, cerebral embolism, spinal cord injury, paralysis, allograft rejection, graft-versus-host disease and bacterial infection. ### Claim 7 A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a peptide selected from the group consisting of one or more of MOP1, MOP2, MOP3, MOP3H, MOP4, MOP5, MOP6, MOP7, MOP8, MOP9, MOP10, MOP11, MOP12, MOP13, MOP14 and MOP15. ### Claim 8 (depends on 7) The pharmaceutical composition of claim 7, wherein the peptide is one or both of MOP3 and MOP3H.